CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection.

Immune evasion is a common hallmark of cancers. Immunotherapies that aim at restoring or increasing the immune response against cancers have revolutionized outcomes for patients, but the mechanisms of resistance remain poorly defined. Here, we report that CD317, a surface molecule with a unique topology that is double anchored into the membrane, protects tumor cells from immunocytolysis. CD317 knockdown in tumor cells renders more severe death in response to NK or chimeric antigen receptor-modified NK cells challenge. Such effects of CD317 silencing might be the results of increasing sensitivity of tumor cells to immune killing rather than strengthening immune response, since neither effector-target cell contact nor the activation of effector cells was affected, and the enhanced cytolysis was also not counteracted by the addition of recombinant CD317 proteins. Mechanistically, CD317 might endow tumor cells with more flexibility to modulate cytoskeleton through its association with RICH2, thereby protects membrane integrity against perforin and consequently promotes survival in response to immunocytolysis. These results reveal a new mechanism of immunocytolysis resistance and suggest CD317 as an attractive target which can be exploited for improving the efficacy of cancer immunotherapies. Copyright © 2020 Elsevier Ltd. All rights reserved.

Citation

Jian Cheng, Zhao Liu, Tian Deng, Zhen Lu, Maoxuan Liu, Xiaoxu Lu, Funmilayo Oladunni Adeshakin, Dehong Yan, Guizhong Zhang, Xiaochun Wan. CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection. Molecular immunology. 2021 Jan;129:94-102

Mesh Tags

Substances

PMID: 33223223

search → result